MedTrace Logo

AlloLife - Life After Transplantation

NCT05087784 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2021-11-16

No results posted yet for this study

Summary

Survivors of allo HCT can experience long-term survival, which is however limited by a number of late effects. These will be addressed in AlloLife to improve quality of life (QoL) and survival.

Conditions

  • Survivorship
  • Stem Cell Transplant Complications

Interventions

COMBINATION_PRODUCT

Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps

Patient-centered, technology-supported integrated survivorship- and care management

Sponsors & Collaborators

  • Universität des Saarlandes

    collaborator OTHER

  • Institut Paoli-Calmettes

    collaborator OTHER

  • Medical University of Warsaw

    collaborator OTHER

  • University Of Perugia

    collaborator OTHER

  • Centre for Research and Technology Hellas

    collaborator OTHER

  • University Hospital, Essen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-31
Primary Completion
2025-12-31
Completion
2026-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05087784 on ClinicalTrials.gov